J. Charton et al. / Bioorg. Med. Chem. Lett. 15 (2005) 4833–4837
4837
´
5. Deprez, B.; Williard, X.; Bourel, L.; Coste, H.; Hyafil, F.;
22. Marrazzo, A.; Prezzavento, O.; Pappalardo, M. S.;
Bousquet, E.; Iadanza, M.; Pike, V. W.; Ronsisvalle, G.
Il Farmaco 2002, 57, 45.
23. Vilner, B. J.; de Costa, B. R.; Bowen, W. D. J. Neurosci.
1995, 15, 117.
Tartar, A. J. Am. Chem. Soc. 1995, 117, 5405.
6. Charton, J.; Delarue, S.; Vendeville, S.; Debreu-Fontaine,
M.-A.; Girault-Mizzi, S.; Sergheraert, C. Tetrahedron
Lett. 2001, 42, 7559.
7. Binding assays of compound 3a were performed on the
following receptors: A1, A2, a1 (nonselective), a2
(nonselective), b1, b2, AT1, B2, L-type calcium channel,
D1, D2L, ERa, GABAA agonist site, GABAA chloride
channel, glucocorticoid, NMDA, glutamate (nonselec-
tive), glycine (strychnine sensitive), H1 (central), H3,
insulin, M1, M2, M3, NY2, nicotinic (central), d, j, l,
phorbol ester, progesterone, P2x, P2y, 5-HT1 (nonselec-
tive), 5-HT2 (sodium channel site 2), NK1, testosterone.
In each case, compound 3a produced less than 30%
inhibition at 10 lM. Binding assays were also per-
formed on the r2 receptor for which compound 3a
produced 63% inhibition at 10 lM and 5% inhibition at
0.1 lM.
8. Bowen, W. D. Pharm. Acta Helv. 2000, 74, 211.
9. Hanner, M.; Moebius, F. F.; Flandorfer, A.; Knaus, H.
G.; Striessnig, J.; Kempner, E.; Glossmann, H. Proc. Natl.
Acad. Sci. U.S.A. 1996, 93, 8072.
10. Kekuda, R.; Prasad, P. D.; Fei, Y. J.; Leibach, F. H.;
Ganapathy, V. Biochem. Biophys. Res. Commun. 1996,
229, 553.
11. Prasad, P. D.; Li, H. W.; Fei, Y. J.; Ganapathy, M. E.;
Fujita, T.; Plumley, L. H.; Yang-Feng, T. L.; Leibach, F.
H.; Ganapathy, V. J. Neurochem. 1998, 70, 443.
12. Mei, J.; Pasternak, G. W. Biochem. Pharmacol. 2001, 62,
349.
13. Senda, K.; Matsuno, K.; Okamoto, K.; Kobajashi,
T.; Nakata, K.; Mita, S. Eur. J. Pharmacol. 1996,
315, 1.
14. Senda, K.; Matsuno, K.; Kobajashi, T.; Nakazawa, M.;
Nakata, K.; Mita, S. Pharmacol. Biochem. Behav. 1998,
59, 129.
15. Kamei, H.; Noda, Y.; Kameyama, T.; Nabeshima, T. Eur.
J. Pharmacol. 1997, 319, 165.
24. Maeda, D. Y.; Williams, W.; Bowen, W. D.; Coop, A.
Bioorg. Med. Chem. Lett. 2000, 10, 17.
25. Huang, Y.; Hammond, P. S.; Wu, L.; Mach, R. H. J. Med.
Chem. 2001, 44, 4404.
26. Chaki, S.; Tanaka, M.; Muramatsu, M.; Otomo, S. Eur. J.
Pharmacol. 1994, 251, R1.
27. Berardi, F.; Santoro, S.; Perrone, R.; Tortorella, V.;
Govoni, S.; Lucchi, L. J. Med. Chem. 1998, 41, 3940.
28. Charton, J.; Cazenave Gassiot, A.; Melnyk, P.; Girault-
Mizzi, S.; Sergheraert, C. Tetrahedron Lett. 2004, 45, 7081.
29. Damour, D.; Barreau, M.; Blanchard, J.-C.; Burgevin,
M.-C.; Doble, A. Chem. Lett. 1998, 9, 943.
30. Burke, S. D.; Danheiser, R. L. Handbook of Reagents for
Organic Synthesis. Oxidizing and Reducing Agents; John
Wiley & Sons: Chichester, 1999, pp 199–200.
31. Brana, M. F.; Garrido, M.; Luz Lopez, M.; de Miguel, P.;
Riano, A. Synth. Commun. 1990, 20, 1793.
´
32. Verschueren, K.; Toth, G.; Tourwe, D.; Lebl, M.; Van
Binst, G.; Hruby, V. Synthesis 1992, 458.
33. r1 receptors were extracted from guinea-pig cerebral cortex
according to Bowen et al.34 Membranes were incubated
with 2 nM [3H](+)pentazocine in 5 mM K2HPO4/KH2PO4
buffer (pH 7.5) for 150 min at 22 °C. Nonspecific binding
was determined under similar conditions but in the presence
of 10 lM unlabelled haloperidol.35
34. Bowen, W. D.; de Costa, B. R.; Hellewell, S. B.; Walker,
M.; Rice, K. C. Mol. Neuropharmacol. 1993, 3, 117.
35. Ganapathy, M. E.; Prasad, P. D.; Huang, W.; Seth, P.;
Leibach, F. H.; Ganapathy, V. J. Pharmacol. Exp. Ther.
1999, 289, 251.
36. r2 receptors were extracted from rat cerebral cortex
according to Bowen et al.34 Membranes were incubated
with 5 nM [3H]DTG (+ 300 nM (+)pentazocine) in 5 mM
K2HPO4/KH2PO4 buffer (pH 7.5) for 120 min at 22 °C.
Nonspecific binding was determined under similar condi-
tions but in the presence of 10 lM unlabelled haloperidol.
37. IC50 values from competitive inhibition experiments were
determined using the Marquardt–Levenberg nonlinear
curve fitting procedure of Xfit macro (Microsoft Excel).
38. Onderwater, R. C. A.; Commandeur, J. N. M.; Groot, E.
J.; Sitters, A.; Menge, W. M. P. B.; Vermeulen, N. P. E.
Toxicology 1998, 125, 117.
16. Bergeron, R.; de Montigny, C.; Debonnel, G. J. Neurosci.
1996, 16, 1193.
17. Maurice, T.; Privat, A. Eur. J. Pharmacol. 1997, 328, 9.
18. Skuza, G. Pol. J. Pharmacol. 2003, 55, 923.
19. Maurice, T.; Martin-Fardon, R.; Romieu, P.; Matsumoto,
R. R. Neurosci. Biobehav. Rev. 2002, 26, 499.
20. Guitart, X.; Codony, X.; Monroy, X. Psychopharmacol-
ogy 2004, 174, 301.
21. Hellewell, S. B.; Bruce, A.; Feinstein, G.; Orringer, J.;
Williams, W.; Bowen, W. D. Eur. J. Pharmacol. 1994,
268, 9.
39. Glennon, R. A.; Ablordeppey, S. Y.; Ismael, A. M.; El-
Ashmawy, M. B.; Fisher, J. B.; Howie, K. B. J. Med.
Chem. 1994, 37, 1214.